Navigation Links
Cambrex Reports Third Quarter 2009 Results
Date:11/3/2009

rther details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit www.cambrex.com.

                            CAMBREX CORPORATION
                       Statement of Profit and Loss
            For the Quarters Ended September 30, 2009 and 2008
                              (in thousands)

                                              2009           2008
                                         -------------   ------------
                                                  % of           % of
                                         Amount  Sales   Amount Sales
                                         -------------   ------------

    Gross Sales                         $57,802  100.0% $56,508 100.0%
         Allowances and Rebates             285    0.5%     193   0.3%
                                        -------         -------
    Net Sales                            57,517   99.5%  56,315  99.7%

         Other Revenues                  (1,147)  -2.0%   1,977   3.5%
                                        -------         -------

    Net Revenues                         56,370   97.5%  58,292 103.2%

         Cost of Goods Sold              39,422   
'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Office (USPTO) has issued a key patent covering ... vaccine targeting six tumor antigens that are commonly ... No. 8,871,211, which issued October 28, 2014, include ... dendritic cell composition comprising peptide epitopes of the ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... December 15, 2014 BerGenBio AS, ... aggressive drug resistant cancers, today announces that it has ... placing from new and existing investors. BerGenBio ... the development of its pipeline of innovative cancer therapeutics, ... lead drug candidate, BGB324, a first-in-class selective Axl kinase ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... DIEGO, March 10, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... today announced financial results for the three months and year ended ... 31, 2010 For the three months ended December ... $0.24 per share, as compared to a net loss of $15.0 ...
... 2011 Dendreon Corporation (Nasdaq: DNDN ) ... (FDA) approved the remainder of its New Jersey manufacturing ... of PROVENGE® (sipuleucel-T) to help meet the needs of ... (hormone refractory) prostate cancer.   Last April, ...
Cached Medicine Technology:Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 2Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 3Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 4Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5
(Date:12/19/2014)... December 19, 2014 Slone ... diagnostic, personalized medicine, healthcare information technology, and laboratory ... position of Chief Operating Officer. The announcement comes ... marked by a strengthened presence in Boston and ... "Leslie lives and breathes the client experience," said ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Being in good ... researchers report. They looked at data from more than ... who underwent treadmill tests between 1991 and 2009. Those ... chance of having high blood pressure at the start of ... with high levels of fitness. Of the more than ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Unidesk ... Osteopathic Medicine (ACOM), which welcomed its inaugural class ... Infrastructure (VDI) to seamlessly support bring your own ... and teaching – experience. The solution, comprised of ... , Dell server and storage infrastructure ...
(Date:12/17/2014)... Miami, FL (PRWEB) December 17, 2014 ... has not been able to eradicate the head louse ... and hassle for parents. Each year between six and ... Lice Troopers, the Miami-based lice removal treatment company comes ... safe, non-toxic and environmentally friendly. With its track record ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... 28 Dr. Eaton E.,Lattman, currently Dean of Research ... and Sciences at Johns Hopkins University (JHU), has,been appointed ... Research Institute. Lattman will assume the,position on July 1, ... has degrees from Harvard and JHU and at JHU ...
... medications longer, study finds , , FRIDAY, March 28 (HealthDay ... than the older drug haloperidol in treating a first ... it appears that more patients prefer the newer drugs ... haloperidol, the study authors said. , "When we compared ...
... Raleigh County League of,Democratic Women will conduct a mock ... Clinton and Barack Obama., "We,re not expecting the ... each one will be represented by two local,volunteers supporting ... be held at 6 p.m. Tuesday at the Raleigh ...
... using whole body 16 multi-detector CT (MDCT); theres no need ... recent study conducted by researchers at the University of Maryland ... in Baltimore, MD. The study showed that whole body MDCT ... In the past, blunt trauma patients would undergo whole-body MDCT ...
... from Boston University School of Medicine (BUSM) and ... found that decreased sexual satisfaction in postmenopausal women, ... study appears in the April 2008 issue of ... dysfunction is a common condition and has been ...
... to try technology like sensors,to detect falls and ... perception, and technical issues remain challenges, WASHINGTON, ... so they can age safely in their home. ... the challenges of caregiving.,Concerns such as cost to ...
Cached Medicine News:Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Whole body MDCT just as 'good' as neck MDCT angiography in diagnosing head and neck injuries 2Health News:Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women 2Health News:Older People Want to Use Technology to Help Them Remain at Home 2Health News:Older People Want to Use Technology to Help Them Remain at Home 3Health News:Older People Want to Use Technology to Help Them Remain at Home 4
8 mm S Graftech cervical spacer....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... system for procedures in the ... system features a broad selection ... for many Craniomaxillofacial procedures. 1.5 ... used predominately in the less ...
... Fixation Systems incorporate a great number ... surgeons and surgical staff. Additionally, the ... either shaped on the spot or, ... cut, bent and shaped implant utilizing ...
Medicine Products: